Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 9.
doi: 10.5435/JAAOS-D-24-01331. Online ahead of print.

Cost Savings of Switching to Aspirin for Thromboprophylaxis in Orthopaedic Trauma Patients: A Budget Impact Analysis

Joseph F Levy  1 , Robert V O'Toole, Deborah M Stein, Elliott R Haut, Katherine P Frey, Renan C Castillo, Nathan N O'Hara; METRC; Major Extremity Trauma Research Consortium (METRC) Corporate Author; METRC and Major Extremity Trauma Research Consortium (METRC) Corporate Author
Collaborators, Affiliations

Cost Savings of Switching to Aspirin for Thromboprophylaxis in Orthopaedic Trauma Patients: A Budget Impact Analysis

Joseph F Levy et al. J Am Acad Orthop Surg. .

Abstract

Introduction: Clinical guidelines recommend low-molecular-weight heparin (enoxaparin) to prevent venous thromboembolism in orthopaedic trauma patients. However, a large trial recently found aspirin noninferior to enoxaparin in preventing death and pulmonary embolism in this population. We modeled cost implications for the United States healthcare system if aspirin replaced enoxaparin as the standard of care for thromboprophylaxis in orthopaedic trauma patients.

Methods: The modeling compared spending under two scenarios: continued use of enoxaparin versus switching to aspirin. The model included fracture incidence estimates from the National Inpatient Sample and dose and duration data from the clinical trial. We derived medication costs from current market prices across payer types and care settings (ie, inpatient and postdischarge prescriptions). The model incorporates uncertainty around each parameter based on calculated standard errors and generates bootstrapped estimates of costs and cost savings disaggregated by the payer.

Results: The results indicated that prescribing enoxaparin for thromboprophylaxis to more than 600,000 fracture patients costs $162.7 million annually, whereas thromboprophylaxis with aspirin would cost $1.6 million annually. Spending on thromboembolic events totals $210.7 million under the enoxaparin scenario and $222.1 million with aspirin. Overall, aspirin for thromboprophylaxis in fracture patients would yield annual savings of $149.7 million (95% credible interval: $97 to $208 million) compared with enoxaparin.

Conclusion: Our findings suggest that a widespread switch from enoxaparin thromboprophylaxis to aspirin would lead to more than $100 million in annual cost savings in the United States alone. Insurers stand to benefit most from this practice change. However, patients, especially those without insurance, would realize considerable savings from aspirin thromboprophylaxis.

Level of evidence: Level 1, Economic.

PubMed Disclaimer

References

    1. Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH: Thromboprophylaxis for trauma patients. Cochrane Database Syst Rev 2013, 2013:CD008303.
    1. Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS: Thromboembolism after trauma: An analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004;240:490-498, discussion 496-498.
    1. Haut ER, Chang DC, Pierce CA, et al.: Predictors of posttraumatic deep vein thrombosis (DVT): Hospital practice versus patient factors-an analysis of the National Trauma Data Bank (NTDB). J Trauma 2009;66:994-1001, discussion 999-1001.
    1. Mull HJ, Borzecki AM, Chen Q, Shin MH, Rosen AK: Using AHRQ patient safety indicators to detect postdischarge adverse events in the Veterans Health Administration. Am J Med Qual 2014;29:213-219.
    1. Kaafarani HM, Borzecki AM, Itani KM, et al.: Validity of selected patient safety indicators: Opportunities and concerns. J Am Coll Surg 2011;212:924-934.